Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.C. Kessler, K.A. McGonagle, S. Zhao, C.B. Nelson, M. Hughes, S. Eshleman, et al.
Lifetime and 12-months prevalence of DSM-III-R psychiatric disorders in United States. Results from the National Comorbidity Survey.
Arch Gen Psychiatry, 51 (1994), pp. 8-19
[2.]
M.J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, et al.
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
J Pharmacol Exp Ther, 306 (2003), pp. 954-964
[3.]
H. Lôo, A. Hale, H. D’Haenen.
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Int Clin Psychopharmacol, 17 (2002), pp. 239-247
[4.]
S.H. Kennedy, R. Emsley.
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Eur Neuropsychopharmacol, 16 (2006), pp. 93-100
[5.]
J.P. Olié, S. Kasper.
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Int J Neuropsychopharmacol, 10 (2007), pp. 661-673
[6.]
G.M. Goodwin, R. Emsley, S. Rembry, F. Rouillon, Agomelatine Study Group.
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
J Clin Psychiatry, 70 (2009), pp. 1128-1137
[7.]
P. Lemoine, C. Guilleminault, E. Álvarez.
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
J Clin Psychiatry, 68 (2007), pp. 1723-1732
[8.]
S.H. Kennedy, S. Rizvi, K. Fulton, J. Rasmussen.
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
J Clin Psychopharmacol, 28 (2008), pp. 329-333
[9.]
S. Kasper, L. Laigle, F. Baylé.
Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study.
Eur Neuropsychopharmacol, 18 (2008), pp. S336
[10.]
A. Hale, R. Corral, G. Mencacci, J. Sáiz Ruiz, C. Albarran Seyero, V. Gentil.
Superior antidepressant efficacy of agomelatine versus fluoxetine in severe major depressive disorder: a randomised, double-blind study.
Eur Neuropsychopharmacol, 19 (2009), pp. S418-S419
[11.]
G.M. Goodwin, F. Rouillon, R. Emsley.
P.2.c.025 long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months.
Eur Neuropsychopharmacol, 18 (2008), pp. S338-S339
[12.]
S.H. Kennedy, R. Emsley.
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
Eur Neuropsychopharmacol, 16 (2006), pp. 93-100
[13.]
S.A. Montgomery, S. Kasper.
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
Int Clin Psychopharmacol, 22 (2007), pp. 283-291
[14.]
M.A. Quera Salva, B. Vanier, J. Laredo, S. Hartley, F. Chapotot, C. Moulin, et al.
Major depressive disorder, sleep EEG and agomelatine: an open-label study.
Int J Neuropsychopharmacol, 10 (2007), pp. 691-696
[15.]
S.H. Kennedy.
Efficacy of agomelatine from treatment initiation to treatment completion.
Eur Neuropsychopharmacol, 18 (2008), pp. S293
El comentario a la ponencia del Prof. Siegfried Kasper ha sido realizado por la Dra. Rosa Hernández-Ribas, del Servicio de Psiquiatría del Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona.
Copyright © 2010. Sociedad Española de Psiquiatría and Sociedad Española de Psiquiatría Biológica